openPR Logo
Press release

Global Scleroderma Therapeutics Market Size & Growth Analysis Report, 2020-2026

05-05-2021 11:28 AM CET | Health & Medicine

Press release from: Orion Market Research

Global Scleroderma Therapeutics Market Size & Growth Analysis

The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare autoimmune disorder about 75,000 to 100,000 people in the US have this disease.

To Request a Sample of our Report on Global Scleroderma Therapeutics Market: https://www.omrglobal.com/request-sample/scleroderma-therapeutics-market

This disease is more common to females between the ages of 30 and 50. As per the United Nations, the global population in 2019 was 7.7 billion, out of which, around 4 billion are females. Out of this, around 50% is the target population in the age range of 15 to 50 years. It is equivalent to around 1.9 billion of the female population. This population is expected to increase to around 2.1 billion by 2025. The rapid increase in the number of the disease-prone population is anticipated to be a key factor contributing to the growth of the scleroderma therapeutics market across the globe.

Boehringer Ingelheim International GmbH, Celgene Corp., arGentis Pharmaceuticals, LLC, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, Inc., Cytori Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Bayer AG, F. Hoffmann La-Roche Ltd., Bristol-Myers Squibb Company, and so on are the prominent players operating in the scleroderma therapeutics market across the globe. The major players of the market are making hefty investments in the R&D of novel therapies for the improved treatment of scleroderma. The continuous efforts of the market players in the development of new therapies are driving the growth of the global market.

(Get 15% Discount on Buying this Report)
A full Report of Global Scleroderma Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/scleroderma-therapeutics-market

The recent development in Market
• In June 2020, Bristol Laboratories Ltd., a UK-based pharmaceutical company had launched Amlodipine besilate tablets in 2.5mg dose. Amlodipine belongs to the class of calcium channel blockers. The launch of this medicine is anticipated to make a contribution to the market growth of scleroderma therapeutics.
• In September 2019, Correvio Pharma Corp. pharmaceutical company focused on commercializing hospital drugs had received US FDA approval to review United Therapeutics Corporation's New Drug Application (NDA) for Trevyent (treprostinil) for the treatment of pulmonary arterial hypertension (PAH).

Global Scleroderma Therapeutics Market Segmentation

By Drug Type

• Phosphodiesterase 5 inhibitors – PHA
• Prostacyclin Analogues
• Immunosuppressors
• Endothelin Receptor Antagonists
• Calcium Channel Blockers
• Others

By Disease Type

• Systemic Scleroderma
• Localized Scleroderma

Regional Analysis

North America
• United States
• Canada

Europe

• UK
• Germany
• Spain
• France
• Italy
• Rest of Europe

Asia-Pacific

• India
• China
• Japan
• Rest oF APAC
Rest of The World

Company Profiles
• arGentis Pharmaceuticals, LLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celgene Corp.
• Chemomab Ltd.
• Corbus Pharmaceuticals Holdings, Inc.
• Cytori Therapeutics Inc.
• Emerald Health Pharmaceuticals, Inc.
• F. Hoffmann La-Roche Ltd.
• Fibrocell Science, Inc.
• Genkyotex
• Kadmon Holdings, Inc.
• Prometic Life Sciences Inc.
• Seattle Genetics, Inc.

Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/scleroderma-therapeutics-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Scleroderma Therapeutics Market Size & Growth Analysis Report, 2020-2026 here

News-ID: 2280175 • Views: 136

More Releases from Orion Market Research

Middle East Fast Food and Quick Service Restaurants Market Size, Share, Impressi …
Middle East's fast food and quick service restaurants market is anticipated to grow with a significant CAGR of 6.7% during the forecast period. The growth of the market is majorly driven by the changing consumer preferences coupled with the growing number of working populations. Additionally, the increasing western culture influence on the young and millennials population across the region is also driving the adoption of fast food. In addition to
Latin America Fast Food and Quick Service Restaurants Market: Analysis Report, S …
Latin America's fast food and quick service restaurants market is anticipated to grow with a significant CAGR of 6.9% during the forecast period. The growth of the market across the region can be attributed to the rapid changes in the diet of the people such as increased away?from?home eating and snacking habits. Additionally, the rapid rise in the number of fast-food chains and quick-service restaurants to comply with the changing
ASEAN Fast Food and Quick Service Restaurants Market: Analysis Report, Share, Tr …
The ASEAN fast food and quick service restaurants market is anticipated to grow with a significant CAGR of 7.2% during the forecast period. The emerging domestic fast-food chains are a major factor propelling the growth of the ASEAN Fast food and quick service restaurants market. Several domestic chains including PT Baba Rafi Enterprise, Jollibee Foods Corp., among others in countries such as Vietnam, Thailand, and Indonesia have more than 1,000
US Fast Food and Quick Service Restaurants Market Size, Share, Impressive Indust …
US fast food and quick service restaurants market is expected to grow with a considerable CAGR of 4.7% during the forecast period. The US-based fast food and quick service restaurants have footprints all across the globe. For instance, Subway has the highest number of location accounting for more than 41,500 locations; similarly McDonald’s Corp. also operates in approximately 38,500 locations across the globe. A full report of US Fast Food and

All 5 Releases


More Releases for Therapeutics

Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018! Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other